4 results
The primary objective is:* To evaluate RBC transfusion independence (RBC-TI) of luspatercept compared with placebo for the treatment of anemia due to IPSS-R very low, low, or intermediate risk MDS in subjects with ring sideroblasts (* 15%) who…
This study aims to validate NI-fECG monitoring as an accurate and reliable monitoring technique for FHR, MHR and UA surveillance during labour. The aim of this validation is to work towards clinical implementation of NI-fECG monitoring.
Primary objective:• To evaluate the efficacy of luspatercept on RBC transfusion independence (RBC-TI for 12 weeks [84 days] with an associated concurrent mean hemoglobin increase >= 1.5 g/dL) compared with epoetin alfa for the treatment of…
To evaluate the efficacy and safety of T-817MA in patients with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease.